Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Amgen, Inc.    AMGN   US0311621009

AMGEN, INC.

 (AMGN)

51
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2013 05/17/2013 05/20/2013 05/21/2013 05/22/2013 Date
104.97(c) 105.63(c) 102.18(c) 104.24(c) 106.46 Last
3 915 388 3 037 993 3 904 902 3 490 307 677 649 Volume
-2.28% +0.63% -3.27% +2.02% +2.13% Change
More quotes
Company
Amgen is one of the world's leading biotechnology groups. Sales break down by source of revenue as follows: - drug sales (96.4%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (3.6%): primarily royalties. 77.7% of sales are in the United... 
Sector
Biotechnology
Calendar
05/22Shareholder meeting
Surperformance© rating of Amgen, Inc.
Trading Rating : Investor Rating :
More about the company
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Financials ($)
Sales 2013 17 955 M
EBIT 2013 6 635 M
Net income 2013 5 127 M
Debt 2013 2 437 M
Yield 2013 1,80%
Sales 2014 18 399 M
EBIT 2014 7 603 M
Net income 2014 5 736 M
Finance 2014 1 658 M
Yield 2014 2,16%
PER 2013 16,26
PER 2014 13,07
EV / Sales 2013 4,49x
EV / Sales 2014 4,16x
Capitalization 78 178 M
More Financials
Latest news on AMGEN, INC.
6d ago AMGEN, INC.: Amgen To Present At The UBS Global Life Sciences Conference
7d ago AMGEN, INC.: Amgen Highlights Data To Be Presented At American Society of Clini..
05/14 AMGEN, INC.: ex-dividend day
05/10DJMedicare Overpaid $529 Million for Anemia Drugs in 2011 - Report
05/09DJAMGEN, INC.: Amgen Forms China Joint Venture
05/09DJAMGEN, INC.: Amgen Forms China Joint Venture With Zhejiang Beta Pharma
05/09 AMGEN, INC.: Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In C..
05/07DJAMGEN, INC.: Amgen Trial of Colon Cancer Drug Meets Goal
05/07DJAMGEN, INC.: Amgen Late-Stage Trial of Colon Cancer Drug Meets Goal
05/02DJTeva Pharmaceutical's Profit Falls on Lower Generic Sales
05/02DJTeva Profit Falls 27% on Lower Generic Sales
05/01DJMerck 1st-Quarter Profit Down on Loss of Singulair Exclusivity
More news
Forum AMGEN, INC.
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
Amgen, Inc. : Income Statement Evolution
More Financials
EPS Revisions
Amgen, Inc. : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.